Trial Profile
Short-term efficacy of aflibercept monotherapy in patients with treatment-naïve polypoidal choroidal vasculopathy (PCV).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 23 Sep 2015 New trial record